OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico

March 20th, 2017|0 Comments

BATON ROUGE, LA--(March 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Announces Term Sheet with EOC Pharma for Development of Telatinib

March 14th, 2017|0 Comments

BATON ROUGE, LA--(March 14, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network

March 13th, 2017|0 Comments

BATON ROUGE, LA--(March 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting

February 2nd, 2017|0 Comments

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, [...]

Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials

January 26th, 2017|0 Comments

BATON ROUGE, LA--(January 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

Departments of Urology and Oncology Approve Protocol for OncBioMune’s Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

January 18th, 2017|0 Comments

OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is [...]

OncBioMune Submitting Clinical Trial of World’s First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute

January 10th, 2017|0 Comments

BATON ROUGE, LA--(January 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer

December 28th, 2016|0 Comments

BATON ROUGE, LA--(December 28, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology

December 12th, 2016|0 Comments

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, [...]

OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer

December 8th, 2016|0 Comments

OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to [...]

OncBioMune Provides Update on Acquisition of Vitel Laboratorios

December 7th, 2016|0 Comments

BATON ROUGE, LA--(December 07, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a [...]

OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition

November 11th, 2016|0 Comments

BATON ROUGE, LA--(November 11, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Signs Term Sheet to Acquire Vitel Laboratorios, S.A. de C.V.

November 3rd, 2016|0 Comments

BATON ROUGE, LA--(November 03, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a [...]

Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board

October 24th, 2016|0 Comments

BATON ROUGE, LA--(October 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax(TM) in Mexico

October 19th, 2016|0 Comments

BATON ROUGE, LA--(October 19, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Pharmaceuticals Announces Shareholder Update

October 7th, 2016|0 Comments

Significant Progress Continues Toward Achieving Key Milestones BATON ROUGE, LA--(October 07, 2016) - OncBioMune Pharmaceuticals Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company [...]

Prostate Cancer Free for 10 Years, Stephen Karalekas Thanks OncBioMune for ProscaVax in Testimonial Video

September 21st, 2016|0 Comments

BATON ROUGE, LA--(September 21, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

OncBioMune Pharmaceuticals in Discussions to Acquire Vitel Laboratorios, S.A. de C.V.

September 14th, 2016|0 Comments

Baton Rouge, Louisiana – September 14, 2016 - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of [...]

Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine

August 8th, 2016|0 Comments

BATON ROUGE, LA--(August 08, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]

Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine

July 20th, 2016|0 Comments

BATON ROUGE, LA--(July 20, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]